Articles tagged with Glioblastomas
A new study finds that Tumor Treating Fields (TTFields) activate the immune system and trigger an anti-tumor cell response, potentially effectively used together with immunotherapy approaches. TTFields' unique mechanism of action induces a downstream signaling pathway that initiates an active immune response against cancer cells.
Researchers at IBiS have developed a new treatment that completely eliminated glioblastoma tumors in animal models, offering a new therapeutic option against this aggressive disease. The therapy combines the use of ADI-PEG20 with focal brain radiotherapy and has shown promising results without side effects.
Four IIT researchers have been awarded €150,000 each from the European Research Council to develop groundbreaking technologies addressing health challenges, such as tumours, blindness, and amputations. Their projects aim to substitute critical raw materials in electronics and create multisensory systems for visually impaired infants.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A clinical trial has found selinexor to be effective in shrinking tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer. The treatment induced responses in certain patients and allowed some to stay on the medication for over 12 months.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers discovered that cyclotides from violets increase the power of TMZ in killing glioblastoma cancer cells by up to eight-fold. This breakthrough could lead to better treatment options for patients with this fatal form of brain cancer.
A new study shows that treating mice with glioblastoma with interleukin-7 in combination with radiation improves survival rates. The therapy increases T cell numbers and activity against cancer cells, offering promise for patients with low lymphocyte counts.
Researchers at VTC have developed a promising three-pronged approach to treating glioblastoma, a lethal brain cancer. By inhibiting two specific proteins with temozolomide, they created an effective 'triple combinational therapy' that overcame chemoresistance.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
A new nomogram tool helps predict patient-level survival probabilities, accounting for sex differences in glioblastoma. The study analyzed over 1,300 patients and recommends further research on biological mechanisms underlying these differences.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
Researchers at Northwestern University have discovered a new biomarker that can identify glioblastoma patients who are likely to respond to immunotherapy. The treatment has shown promise in prolonging the lives of patients with this malignant brain tumor, which currently has a poor prognosis.
A UCLA research team found that PD-1 blockade initially activates T cells and conventional dendritic cells in glioblastoma, but the immune microenvironment remains dominated by immunosuppressive cells. The study suggests that combining therapies targeting other checkpoint proteins and pathways may improve treatment outcomes.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
A study has identified a specific protein, PHF3, that plays an important role in transcription and modulates the reading process of DNA. The absence of PHF3 or its binding site SPOC may lead to neuronal production defects, which could be linked to autism and glioblastoma.
Researchers at Queen Mary University of London have discovered a new way to analyze diseased and healthy cells from the same patient, revealing potential targets for individualized treatments. The study's findings could also help predict patient response to current drugs, leading to improved survival rates.
A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.
A new study found that translocator protein 18 kDa (TSPO) correlates with worse survival outcomes in male glioblastoma patients compared to females. The variation in the protein's structure is associated with shorter overall and progression-free survival times, suggesting its potential as a prognostic biomarker.
A new antibody delivery technology enhances anti-PD-L1 antibody accumulation in glioblastoma by 33-fold, achieving a 60% complete response rate with long-term immune memory. The technology also suppresses immune-related adverse events.
Researchers developed a gel made of fibrin that improved the effectiveness of CAR-T cell immunotherapy for glioblastoma by enhancing T cell distribution and preventing tumor recurrence. In mouse studies, the gel showed promising results, with 64% of treated mice being tumor-free after 94 days.
Researchers at the University of Alabama at Birmingham discovered a small molecule that potently attenuates neuroinflammation in brain and glial cells. This finding presents a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury, and neuropathic pain.
Researchers from NUS Yong Loo Lin School of Medicine have discovered that glioblastoma cells depend on biotin distribution to grow and invade. This finding suggests that targeting biotin-dependent metabolic enzymes and epigenetic pathways may be a viable approach for treating glioblastoma.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers have developed poly-ion complex (PIC) nanomicelles loaded with CPT1A inhibitors to deliver drugs into brain cells, reducing fatty acid oxidation and improving treatment for glioblastoma. The delivery system successfully increased cellular concentration of the cargo and biological activity.
The study confirms the upregulation of TERT in primary glioblastomas and the gradual expression of all GABP components during malignancy progression. The authors found a positive association between TERT and B1L mRNA expression, highlighting the importance of GABPA/B isoforms in mutated TERT promoter-dependent gliomas.
Researchers at Houston Methodist used a helmet generating a noninvasive oscillating magnetic field to treat end-stage recurrent glioblastoma. The treatment resulted in a 31% reduction of the tumor mass, with significant shrinkage appearing to correlate with the treatment dose.
Researchers discovered that glioblastoma (GBM) causes epigenetic changes in CD4 T-cells, affecting their function and differentiation. The study found significant inter-patient variability in these changes, which could help select patients for immunotherapy.
A new study reveals similarities between glioblastoma and melanoma, as well as unique immunosuppressive factors specific to glioblastoma microenvironment. This framework can be used to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies.
Researchers discovered that laminins, specifically laminin γ1, play a crucial role in mediating cell attachment and penetration for oncolytic viruses like H-1PV. This finding may lead to the development of more efficient clinical trials with reduced costs and approval times.
Researchers discovered hematopoietic stem cells in glioblastomas, which promote division of cancer cells and suppress the immune response. These blood stem cells stimulate tumor growth and produce immunosuppressive messengers.
The company's 3D Predict assay has been validated for predicting responses to temozolomide in glioblastoma patients, with predictive accuracy comparable to its previous results in ovarian cancer. The test identifies future responders and non-responders, enabling personalized treatment strategies.
Researchers engineered NK cells to resist immune suppression and eliminated glioblastoma stem cells using inhibitors targeting TGF-β receptors. The study suggests a combinatorial approach of NK cell-based immunotherapy with disruption of the TGF-β signaling axis for treating glioblastoma.
A British man diagnosed with IDH1-mutant glioblastoma has lived with a growing tumor for over 80 months on a ketogenic diet. Researchers believe this reflects the benefits of using the body's own metabolism to fight cancer, offering a non-toxic alternative to chemotherapy and radiation therapy.
Researchers discovered MCAD's protective role in glioblastoma cells, which relies on the enzyme to detoxify toxic byproducts of fatty acid metabolism. Inhibiting MCAD appears to be specific and potent in killing glioblastoma cells.
Researchers identify a new class of mibefradil-based DNA repair inhibitors, which could be further advanced into pre-clinical testing and eventually clinical trials for glioblastoma radiosensitization. The compounds retain potency as DNA repair inhibitors while demonstrating reduced hERG and CYP450 enzyme inhibition.
Researchers at Massachusetts General Hospital have developed a strategy to reprogram regulatory T cells in the brain to attack glioblastoma tumors. By targeting a specific receptor on these cells, they can convert them into tumor-fighting immune cells, offering a possible solution to overcome resistance to immunotherapy.
A team of researchers from Virginia Tech and City of Hope aim to improve CAR-T cell therapy for glioblastoma multiforme by studying the impact of fluid flow on the treatment's success. They believe they can use fluid flow to encourage T cells to move deeper into tumors and kill invading cancer cells.
Researchers found that piperlongumine binds to and inhibits TRPV2 protein, which is overexpressed in glioblastoma, a type of brain cancer. The treatment radically shrank tumors and extended life in two mouse models.
Researchers at the University of Minnesota identified a new drug target for glioblastoma patients who defy conventional wisdom by surviving beyond expectations. Glioblastoma cells subvert immune system cells called microglia and macrophages, leading to tumor growth.
A new biomedical implant, microMESH, has been developed to treat glioblastoma multiforme. The device wraps around tumor masses, delivering drugs in a controlled, prolonged manner, increasing therapeutic efficacy.
Researchers propose a novel therapeutic strategy combining temozolomide with dianhydrogalactitol to overcome resistance mechanisms in glioblastoma. The combination shows synergistic effects in slowing tumour growth, suggesting a promising new approach for treating aggressive brain tumors.
A new study has found that inhibiting a protein called SELP can block the spread of Glioblastoma cancer cells in the brain. By doing so, the treatment may be able to slow down or even halt the progression of this deadly type of brain cancer.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
Researchers at VCU Massey Cancer Center have identified a crucial link between the development and growth of glioblastoma multiforme, the most aggressive type of brain cancer. The gene YTHDF2 drives increased cholesterol levels in GBM cells, paving the way for potential new treatments targeting this gene.
A new study mapped glioblastoma in genetic and molecular detail, revealing four distinct immune subtypes and potential targets for therapy. The research identified key signaling hubs, gene expression patterns and protein modifications that drive tumor growth.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new approach combining an anti-psychotic drug, a statin and radiation to improve overall survival in mice with glioblastoma. The triple combination extended median survival 4-fold compared to radiation alone, providing hope for improved treatment options.
Researchers developed a new method to classify brain tumors using RNA analysis, achieving high accuracy rates compared to traditional methods. The study found that this approach can identify patients with a worse prognosis and detect secondary glioblastomas not detected by other methods.
Researchers at McGill University identified a new cellular pathway controlling cell surface receptor proteins that limits brain tumor growth and spread. Restoring the activity of Rab35, a protein involved in this pathway, may be a new therapeutic strategy for glioblastoma.
Researchers found that brain tumour growth may be triggered by mutations in cells generated to replace damaged tissue after an injury. The study provides new insights into how glioblastoma develops and could lead to targeted therapies.
Researchers have developed molecular reporters that reveal how immune cells strengthen brain tumors, making them more aggressive. The technology has the potential to guide therapy development and is applicable to various biological systems.
The Luxembourg Institute of Health (LIH) research team discovered a key regulator, ZFAND3, that drives glioblastoma invasion by activating specific genes. Deactivating or overexpressing ZFAND3 in GBM cells impaired or enhanced their invasive capabilities, respectively.
Research found that neutrophils, a type of white blood cell, cause tissue death in brain cancer tissues, leading to poor survival rates for glioblastoma patients. The study identified ferroptosis as the underlying mechanism, which promotes tumor growth.
Researchers found that concurrent dexamethasone administration with an immune checkpoint inhibitor reduced survival in both immunosensitive and immunoresistant mouse models. In human patients, those taking dexamethasone at baseline had significantly worse overall survival compared to non-users.
Researchers have created a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma, showing improved survival rates in mice. The developed nanomicelle accurately senses the pH lowering in tumor tissue and releases the contained anticancer drug.
A phase II trial found no statistically significant overall survival differences between dose-intensification radiation therapy (IMRT) and standard-dose radiation therapy with temozolomide treatments. However, MGMT methylation and RPA were predictive of progression-free survival.